Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

1.725 -0.025 (-1.43%)
Streaming Delayed Price Updated: 10:41 AM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,521,621
Open 1.700
Bid (Size) 1.720 (134)
Ask (Size) 1.730 (163)
Prev. Close 1.750
Today's Range 1.670 - 1.745
52wk Range 1.639 - 12.51
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-77.9%
-77.9%
1 Month
-46.3%
-46.3%
3 Month
-69.3%
-69.3%
6 Month
-79.1%
-79.1%
1 Year
-83.3%
-83.3%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
From Pomerantz LLP
Via GlobeNewswire
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
From SkyMedia, LLC
Via GlobeNewswire
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
From The Rosen Law Firm PA
Via GlobeNewswire
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Exposures Economy Legal Product Safety
FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action
From Kahn Swick & Foti, LLC
Via GlobeNewswire
Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
Via The Motley Fool
Deadline Approaching: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
IOVA BREAKING NEWS: Iovance Biotherapeutics, Inc. Stock Plummets 44% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:IOVA)
From Bleichmar Fonti & Auld LLP
Via Business Wire
Law Offices of Frank R. Cruz Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors To Inquire About Securities Fraud Class Action
From The Law Offices of Frank R. Cruz
Via Business Wire
Deadline Alert: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
Kaplan Fox Encourages Investors of Iovance Biotherapeuitcs, Inc. (IOVA) to Contact the Firm Before Lead Plaintiff Deadline on July 14, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox Encourages Investors of Iovance Biotherapeuitcs, Inc. (IOVA) to Contact the Firm Before Lead Plaintiff Deadline on July 14, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
From Pomerantz LLP
Via GlobeNewswire
IOVA Investors Have the Opportunity to Lead the Iovance Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to a Securities Class Action Deadline on July 14, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox Alerts Investors of Iovance Biotherapeutics, Inc. (IOVA) to a Securities Class Action Deadline on July 14, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action
From Kahn Swick & Foti, LLC
Via Business Wire
IOVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Iovance Biotherapeutics Tumbled by Nearly 6% Today
Via The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Kaplan Fox Alerts Investors to a Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA) - Deadline is July 14, 2025
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox Alerts Investors to a Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA) - Deadline is July 14, 2025
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 1.725
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 05/23/25 10:41 AM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 526.56M
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 527M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.